Press Releases

Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022 Continuing to seek opportunities to generate

Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations. In this advisory role, Dr.

Two Abstracts Support Company’s Targeted Therapeutics Program including the Drug Delivery System SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted

Provides educational resources for both patients and healthcare providers SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health,

Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with verification study and demonstrated commercial laboratory systems readiness Announced funding from the Crohn’s

Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn’s & Colitis Foundation’s IBD

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13,

Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing